The hair guru explains how he opened up the first dermatology practice dedicated to hair, pearls from his session, innovative therapies, and research he has recently submitted.
How will new federal law affect lives and wallets of physicians?
In 2023 as many as 11 biosimilars to Humira are headed for the US market.
Amy Paller, MD, reviews the various types of therapeutics available and coming soon for pediatric atopic dermatitis and how she decides what treatment approach is best for each patient.
Delgocitinib is first-in-class pan-Janus kinase inhibitor.
Kirby presented at both Fall Clinical and the Inflammatory Disease Summit in Las Vegas.
The clinical and histologic subtypes encompassed by granulomatous dermatitis include palisaded neutrophilic granulomatous dermatitis and interstitial granulomatous dermatitis. This review compares the features of each cutaneous eruption.
Ami Greene, MD, discusses her beginner and intermediate SDPA fall conference sessions on dermoscopy.
Three distinct congresses known as RAVE (Revolutionizing Atopic Dermatitis, Alopecia Areata, and Vitiligo) will be held June 8-10, in Chicago, Illinois.
By integrating capabilities and services, we can create health experiences that are much more than the sum of their parts.
Joel Schlessinger, MD, shares his atopic dermatitis insights.
The clinical and histologic subtypes encompassed by granulomatous dermatitis include palisaded neutrophilic granulomatous dermatitis and interstitial granulomatous dermatitis. This review compares the features of each cutaneous eruption.
From explaining how medications work and should be taken to reviewing potential adverse effects and financial details, pharmacists are crucial resources for patients undergoing treatment for skin cancer.
Medical networks and smaller practices alike are facing spiraling inflation costs and staffing shortfalls due to waves of COVID cases that are impacting physicians, staff, and management.
Hyaluronic acid fillers and biostimulators were a couple of Prather's recent favorite aesthetic advancements.
An expert in dermatology shares her thoughts at AAD on the sun protection needs in her patients with skin of color; highlighting the role of the Fitzpatrick skin type scale and compounds such as vitamin E and antioxidants.
Closing out their discussion on the management of plaque psoriasis, panelists share their excitement for future directions in care.
In online discussion April 23, commissioners cited health care specifically among their reasons for supporting the ban.
New data from ADORING 1 and ADORING 2 show a rapid reduction in pruritus relief as early as 24 hours after the first application.
Erin Boh, MD, emphasizes the importance of patient empowerment and physician education surrounding the management of GPP.
Alexandra Kimball, MD, FAAD, reviews late-breaking data at AAD on lutikizumab for hidradenitis suppurativa.
In the final part of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, review 4 real-world clinical cases of BCC and the treatments they utilized.
In late 2020, our sister publication, Medical Economics®, conducted a Physicians Report asking physician audiences what they thought would be the most challenging issues they will face this year. Here is what the respondents said.
Takeaways from a panel discussion on newer biologic therapies to treat plaque psoriasis, and parting advice to other professionals who work in dermatology regarding best practices when using these drugs in their clinics.
Miranti previews her sessions from the meeting which kicks off tomorrow, May 30, in Orlando, Florida.
The dietary supplement industry seeks to help consumers age gracefully.